A recent study by researchers at the University of Florence and collaborators has demonstrated the efficacy of MRS-3997, a dual adenosine A2A/A2B receptor agonist, in reducing brain damage and ...

Peter Molloy, CEO of Cyncado Therapeutics, commented: “The adenosine pathway offers immense potential in immuno-oncology, and our A2a and A2b receptor antagonists are among the most promising ...

Peter Molloy, CEO of Cyncado Therapeutics, commented: “The adenosine pathway offers immense potential in immuno-oncology, and our A2a and A2b receptor antagonists are among the most promising ...